Advertisement

Arevir: A Secure Platform for Designing Personalized Antiretroviral Therapies Against HIV

  • Kirsten Roomp
  • Niko Beerenwinkel
  • Tobias Sing
  • Eugen Schülter
  • Joachim Büch
  • Saleta Sierra-Aragon
  • Martin Däumer
  • Daniel Hoffmann
  • Rolf Kaiser
  • Thomas Lengauer
  • Joachim Selbig
Part of the Lecture Notes in Computer Science book series (LNCS, volume 4075)

Abstract

Despite the availability of antiretroviral combination therapies, success in drug treatment of HIV-infected patients is limited. One reason for therapy failure is the development of drug-resistant genetic variants. In principle, the viral genomic sequence provides resistance information and could thus guide the selection of an optimal drug combination. In practice however, the benefit of this procedure is impaired by (1) the difficulty in inferring the clinically relevant information from the genotype of the virus and (2) the restricted availability of this information. We have developed a secure platform for collaborative research aimed at optimizing anti-HIV therapies, called Arevir. A relational database schema was designed and implemented together with a web-based user interface. Our system provides a basis for monitoring patients, decision-support, and computational analyses. Thus, it merges clinical, diagnostic and bioinformatics efforts to exploit genomic and patient therapy data in clinical practice.

Keywords

Viral Genomic Sequence Genotypic Resistance Test Statistical Learning Method Relational Database Schema Secure Platform 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stanic, A., Schneider, T.K.: Overview of Antiretroviral Agents in 2005. Journal of Pharmacy Practice 18, 228–246 (2005)CrossRefGoogle Scholar
  2. 2.
    Marcello, A.: Latency: the hidden HIV-1 challenge. Retrovirology 3, 7 (2006)CrossRefGoogle Scholar
  3. 3.
    Powderly, W.G.: Long-term exposure to lifelong therapies. J. Acquir. Immune. Defic. Syndr. 29(suppl. 1), S28–S40 (2002)Google Scholar
  4. 4.
    Perrin, L., Telenti, A.: HIV treatment failure: testing for HIV resistance in clinical practice. Science 280, 1871–1873 (1998)CrossRefGoogle Scholar
  5. 5.
    Walter, H., Schmidt, B., Korn, K., Vandamme, A.M., Harrer, T., Uberla, K.: Rapid, phenotypic HIV-1 drug sensitivity assay for protease and reverse transcriptase inhibitors. J. Clin. Virol. 13, 71–80 (1999)CrossRefGoogle Scholar
  6. 6.
    Shafer, R.W., Kantor, R.J., Gonzales, M.J.: The Genetic Basis of HIV-1 Resistance to Reverse Transcriptase and Protease Inhibitors. AIDS Rev. 2, 211–228 (2000)Google Scholar
  7. 7.
    De Gruttola, V., Dix, L., D’Aquila, R., Holder, D., Phillips, A., Ait-Khaled, M., Baxter, J., Clevenbergh, P., Hammer, S., Harrigan, R., Katzenstein, D., Lanier, R., Miller, M., Para, M., Yerly, S., Zolopa, A., Murray, J., Patick, A., Miller, V., Castillo, S., Pedneault, L., Mellors, J.: The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir. Ther. 5, 41–48 (2000)Google Scholar
  8. 8.
    Kuiken, C., Korber, B., Shafer, R.W.: HIV sequence databases. AIDS Rev. 5, 52–61 (2003)Google Scholar
  9. 9.
    Wang, D., Bloor, S., Larder, B.A.: The application of neural networks in predicting phenotypic resistance from genotypes for HIV-1 protease inhibitors. Antivir. Ther., 51–52 (2000)Google Scholar
  10. 10.
    Sevin, A.D., DeGruttola, V., Nijhuis, M., Schapiro, J.M., Foulkes, A.S., Para, M.F., Boucher, C.A.: Methods for investigation of the relationship between drug-susceptibility phenotype and human immunodeficiency virus type 1 genotype with applications to AIDS clinical trials group 333. J. Infect. Dis. 182, 59–67 (2000)CrossRefGoogle Scholar
  11. 11.
    Beerenwinkel, N., Schmidt, B., Walter, H., Kaiser, R., Lengauer, T., Hoffmann, D., Korn, K., Selbig, J.: Geno2pheno: Interpreting Genotypic HIV Drug Resistance Tests. IEEE Intelligent Systems in Biology, 35–41 (2001)Google Scholar
  12. 12.
    Beerenwinkel, N., Schmidt, B., Walter, H., Kaiser, R., Lengauer, T., Hoffmann, D., Korn, K., Selbig, J.: Diversity and complexity of HIV-1 drug resistance: a bioinformatics approach to predicting phenotype from genotype. Proc. Natl. Acad. Sci. USA 99, 8271–8276 (2002)CrossRefGoogle Scholar
  13. 13.
    Cordes, F., Kaiser, R., Selbig, J.: Bioinformatics approach to predicting HIV drug resistance. Expert Rev. Mol. Diagn. 6, 207–215 (2006)CrossRefGoogle Scholar
  14. 14.
    Tierney, W.M.: Improving clinical decisions and outcomes with information: a review. Int. J. Med. Inform. 62, 1–9 (2001)CrossRefGoogle Scholar
  15. 15.
    Marshall, W.W., Haley, R.W.: Use of a secure Internet Web site for collaborative medical re-search. Jama 284, 1843–1849 (2000)CrossRefGoogle Scholar
  16. 16.
    Schoenberg, R., Safran, C.: Internet based repository of medical records that retains patient confidentiality. Bmj 321, 1199–1203 (2000)CrossRefGoogle Scholar
  17. 17.
    Mandl, K.D., Szolovits, P., Kohane, I.S.: Public standards and patients’ control: how to keep electronic medical records accessible but private. Bmj 322, 283–287 (2001)CrossRefGoogle Scholar
  18. 18.
    Diffie, W., Hellman, M.: New directions in cryptography. IEEE Transactions on Information Theory, 472–492 (1976)Google Scholar
  19. 19.
    Rivest, R.L., Shamir, A., Adleman, L.: A method for obtaining digital signatures and public-key cryptosystems. Communications of the ACM, 120–126 (1978)Google Scholar
  20. 20.
    Secure Hash Standard. FIPS PUB. Federal Information Processing Standards (1995)Google Scholar
  21. 21.
    Beerenwinkel, N., Daumer, M., Oette, M., Korn, K., Hoffmann, D., Kaiser, R., Lengauer, T., Selbig, J., Walter, H.: Geno2pheno: Estimating phenotypic drug resistance from HIV-1 genotypes. Nucleic Acids Res. 31, 3850–3855 (2003)CrossRefGoogle Scholar
  22. 22.
    Sing, T., Sander, O., Beerenwinkel, N., Lengauer, T.: ROCR: visualizing classifier performance in R. Bioinformatics 21, 3940–3941 (2005)CrossRefGoogle Scholar
  23. 23.
    Sirois, S., Sing, T., Chou, K.C.: HIV-1 gp120 V3 loop for structure-based drug design. Curr. Protein Pept. Sci. 6, 413–422 (2005)CrossRefGoogle Scholar
  24. 24.
    Beerenwinkel, N., Sing, T., Lengauer, T., Rahnenfuhrer, J., Roomp, K., Savenkov, I., Fischer, R., Hoffmann, D., Selbig, J., Korn, K., Walter, H., Berg, T., Braun, P., Fatkenheuer, G., Oette, M., Rockstroh, J., Kupfer, B., Kaiser, R., Daumer, M.: Computational methods for the design of effective therapies against drug resistant HIV strains. Bioinformatics 21, 3943–3950 (2005)CrossRefGoogle Scholar
  25. 25.
    Beerenwinkel, N., Lengauer, T., Daumer, M., Kaiser, R., Walter, H., Korn, K., Hoffmann, D., Selbig, J.: Methods for optimizing antiviral combination therapies. Bioinformatics 19(suppl.1), 16–25 (2003)CrossRefGoogle Scholar
  26. 26.
    Beerenwinkel, N., Daumer, M., Sing, T., Rahnenfuhrer, J., Lengauer, T., Selbig, J., Hoffmann, D., Kaiser, R.: Estimating HIV evolutionary pathways and the genetic barrier to drug resistance. J. Infect. Dis. 191, 1953–1960 (2005)CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2006

Authors and Affiliations

  • Kirsten Roomp
    • 1
  • Niko Beerenwinkel
    • 2
  • Tobias Sing
    • 1
  • Eugen Schülter
    • 3
  • Joachim Büch
    • 1
  • Saleta Sierra-Aragon
    • 4
  • Martin Däumer
    • 4
  • Daniel Hoffmann
    • 3
  • Rolf Kaiser
    • 4
  • Thomas Lengauer
    • 1
  • Joachim Selbig
    • 5
  1. 1.Max Planck Institute for InformaticsSaarbrückenGermany
  2. 2.Department of MathematicsUniversity of CaliforniaBerkeleyUSA
  3. 3.Center of Advanced European Studies and Research (caesar)BonnGermany
  4. 4.Institute of VirologyUniversity of CologneKölnGermany
  5. 5.University of Potsdam and Max Planck Institute for Molecular Plant PhysiologyGolm-PotsdamGermany

Personalised recommendations